

Document type	SOP (Standard Operating Procedure)					
Intended for	Chair, Secretary and members of the Local Bioethics Committee of HemCenter LLP					
Nomenclature code	I-05	Number	Issl-3-19	Revision	001	
Title	EXTRAORDINARY LEC MEETINGS					
Developed by	Business Development Director		Volyanskaya N.V.		15 May 2023	
	Project Manager		Graf M.A.		15 May 2023	
Agreed by	Medical Director		Klodzinskiy A.A.		29 May 2023	
	Head of Patient Support and Internal Review Service		Demkina O.V.		29 May 2023	
Approved	By Order of the Director General of HemCenter LLP No. I-02-52 dated 2 June 2023					
Implemented						
Revision policy	Upon changes in regulatory legal acts and/or operational need					

Purpose

To establish the procedure for organising an extraordinary (emergency) meeting and to provide instructions for the review and approval of research activities by holding an emergency meeting of the Local Bioethics Committee of HemCenter LLP

Responsibilities

The Chair of the Local Bioethics Committee of HemCenter LLP is responsible for convening and holding the extraordinary meeting

Contents

- Terms and definitions
- Abbreviations
- Procedure
- Governing documents
- Related documents
- List of changes
- Document acknowledgement list

No. Terms and definitions

- a. **Biological equivalence** (hereinafter – bioequivalence) – the absence of significant differences in the rate and extent to which the active substance or active moiety of pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of its action when administered at the same molar dose under similar conditions in an appropriately designed study
- a. **Investigator's Brochure** - a compilation of the results of the clinical and preclinical (non-clinical) study of the investigational product that are relevant to its study in humans.
- b. **State expert organization in the field of circulation of medicinal products and medical devices** (hereinafter – the expert organization) – a state monopoly entity carrying out production and economic activities in the field of healthcare to ensure the safety, efficacy and quality of medicinal products and medical devices.
- c. **Study design** - the overall plan of the study, a description of the manner in which the study is conducted depending on the selection and formation of groups of study subjects and the blinding (masking) of data.
- d. **Contract** - a dated and signed agreement between two or more parties that sets out arrangements concerning the allocation of the scope of work and responsibilities in the conduct of a study and, where necessary, financial matters. The study protocol should serve as the basis of the contract.
- e. **Case report form** - a document on paper, electronic or optical media designed to record all the information required by the protocol to be reported to the sponsor on each study subject.

Type	SOP	Nomenclature code	I-05	Number	Issl-3-19	Revision	001
Title	EXTRAORDINARY LEC MEETINGS						

- f. **Interventional study** – a study involving a human as a study subject, in which the investigator-physician, on the basis of an interventional clinical trial protocol that complies with the procedure for conducting clinical trials, assigns a specific intervention to the study subjects.
- g. **Informed consent** - a procedure by which a study subject or his or her legal representative voluntarily confirms consent to participate in a particular study after having been informed of all aspects of the study that are relevant to the decision. Written informed consent is documented using the form approved by the authorized body.
- h. **Bioequivalence study** – a comparative study of bioavailability aimed at establishing pharmacokinetic equivalence between the test product and the comparator product.
- i. **Investigator** - an individual responsible for the conduct of a clinical trial at the clinical sites of HemCenter LLP, a member of the research team.

Where a study is conducted at a clinical site by a group of investigators, a **Principal Investigator** - the head of the research team - is designated. The Principal Investigator is selected by the members of the Clinical Project Office and approved by the Director General of HemCenter LLP. The Order appointing the members of the research team (investigators) is approved by the directors of the branches and the division of HemCenter LLP

- j. **Investigational product** - a pharmaceutical form of an active substance or placebo being tested or used as a control in a clinical trial, including an authorised medicinal product where it is used in a way different from the approved one, or when used for a new indication or to gain further information about an approved indication
- k. **Ethics committee** - a consultative and advisory body established at the national level (the Central Bioethics Commission) and at the level of a medical organization, composed of specialists in healthcare and science and representatives of public organizations, which protects the rights, safety and well-being of study subjects and investigators and carries out the ethical and moral-legal assessment of clinical trial materials.

Local Bioethics Committee (LEC) of HemCenter LLP - an independent body that protects the rights, safety and well-being of patients, trial subjects, investigators and healthcare workers and carries out the ethical and moral-legal assessment of materials related to medical and scientific activities.

- l. **Clinical site** - a healthcare organization that conducts clinical trials.
- m. **Clinical trial** - a study involving a human as a subject, conducted to identify or confirm the safety and efficacy of means, methods and technologies for the prevention, diagnosis and treatment of diseases.
- n. **Contract research organization (CRO, Contract research organization)** — an individual/organization that, under a contract with the sponsor, performs one or more of the sponsor's functions related to the conduct of a clinical trial.
- o. **Confidentiality** - keeping information belonging to the sponsor, or information that makes it possible to identify a study subject, secret from unauthorized persons. Materials containing restricted information.
- p. **Medicinal product** – a product that is or contains a substance or combination of substances that comes into contact with the human body and is intended for the treatment or prevention of human diseases, or for restoring, correcting or modifying human physiological functions by exerting a pharmacological, immunological or metabolic action, or for the diagnosis of human diseases and conditions.
- q. **Study materials** – a set of documents submitted by the sponsor of clinical trials to the clinical site, which includes the authorization of the authorized body in the field of healthcare of the Republic of Kazakhstan to conduct the given clinical trial and to designate those responsible for its conduct in accordance with the procedure approved in the Republic of Kazakhstan; the clinical trial protocol; the Investigator's Brochure; explanatory documents on the specifics of the use of new medical technologies (where used) and other documents, as well as the draft clinical trial contract
- r. **Medical record** — a medical document in which the attending physicians record the patient's medical history (inpatient or outpatient) and the treatment prescribed to the patient, in electronic or paper form.
- s. **Multicenter clinical trial** - a clinical trial conducted according to a single protocol at more than one study center and by more than one investigator.
- t. **Clinical trial monitor** – an individual appointed by the sponsor or contract research organization who works together with the coordinating investigator or coordinating committee and oversees the conduct of the clinical

Type	SOP	Nomenclature code	I-05	Number	Issl-3-19	Revision	001
Title	EXTRAORDINARY LEC MEETINGS						

trial in accordance with the protocol, assesses the degree of its implementation, and assists the investigator in the analysis, interpretation and extrapolation of data.

- u. **Monitoring** - the procedure of overseeing the progress of a biomedical study and ensuring that it is conducted, the data are collected and the study results are reported in accordance with the protocol, plan, programme, standard operating procedures and Good Clinical Practice.
- v. **Good Clinical Practice (GCP)** - a standard for the design, organization, conduct, monitoring, auditing and recording of clinical trials, as well as for the analysis and reporting of their results, that provides assurance that the data obtained and the results reported are credible and accurate, and that the rights, health and confidentiality of study subjects are protected.
- w. **Adverse incident** – any malfunction and/or deterioration in the characteristics or performance of a medical device, or any inadequacy or inaccuracy in the accompanying information (documentation) for a medical device, or side effects or an adverse reaction not specified in the instructions for use or the operating manual, which directly or indirectly led, or might have led, to the death or serious deterioration in the state of health of users or third parties.
- x. **Adverse event** – any untoward change in the state of health of a patient or clinical trial (study) subject administered a medicinal (investigational) product, regardless of whether it has a causal relationship with its use.
- y. **Impartial witness** - an individual not involved in the conduct of the clinical trial, - who assists the study subject, including by reading out the written materials supplied to him or her.
- z. **Non-interventional clinical trial** – a study that is conducted after the state registration of a medicinal product or medical device and is prescribed within the framework of medical practice.
- aa. **Original medical records** – see the term "source documents".
- bb. **Essential documents** – documents which collectively or individually permit evaluation of the conduct of a study and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor and monitor with the standards of Good Clinical Practice (GCP) and with regulatory requirements.
- cc. **Clinical trial (study) report** - a document containing a description of a clinical trial of a therapeutic, prophylactic or diagnostic agent involving a human as a subject, which integrates the clinical and statistical descriptions, the presentation of data and their analysis; and long-term effects, including adverse reactions to the investigational medicinal product or medical device.
- dd. **Source documents** – all information contained in original medical records and certified copies thereof that describes the results of clinical observations, examinations and other activities and makes it possible to reconstruct and evaluate the course of the clinical trial. Source data are contained in source documents (originals or certified copies thereof).
- ee. **Comparator product** – an authorised medicinal product or placebo used as a control in a clinical trial.
- ff. **Clinical trial protocol** - a document that describes the objectives, design, methodology, statistical considerations and organization of a study.
- gg. **Serious adverse event and/or serious adverse reaction** - an adverse reaction that results in death, is life-threatening, requires hospitalization of the patient or prolongation of existing hospitalization, results in persistent or significant incapacity or disability, or in congenital anomalies or birth defects, or requires medical intervention to prevent the development of the listed conditions
- hh. **Protocol synopsis** - a brief summary of the clinical trial protocol.
- ii. **Clinical trial sponsor** – an individual or legal entity responsible for the initiation, organization and financing of a clinical trial.
- jj. **Standard operating procedures** – detailed written instructions designed to achieve uniformity in the performance of a specific activity.
- kk. **Study subject** - an individual who participates in a clinical trial either as part of the group receiving the investigational product or as part of the control group.

Type	SOP	Nomenclature code	I-05	Number	Issl-3-19	Revision	001
Title	EXTRAORDINARY LEC MEETINGS						

II. **Authorized body** in the field of healthcare – the Ministry of Health of the Republic of Kazakhstan.

mmClinical trial phase:

the first phase of a clinical trial – the first testing of a medicinal product, conducted in healthy volunteers or, where the high toxicity of the investigational product makes it unethical to conduct the study in healthy volunteers, in patients suffering from the relevant disease, in order to establish tolerability, safety, the presence of a therapeutic effect, and pharmacokinetic and pharmacodynamic characteristics;

the second phase of a clinical trial – a study aimed at assessing the efficacy and short-term safety of the investigational medicinal product in patients with a specific disease, as well as demonstrating the clinical efficacy of the medicinal product and determining the therapeutic dose level when tested in a group of patients;

phase four of a clinical trial – a study of a medicinal product conducted after its registration and placing on the market in order to confirm its therapeutic efficacy and the strategy for its further use, as well as to obtain additional information on the range and frequency of adverse effects and on the interaction of the investigational medicinal product with other medicinal products;

phase three of a clinical trial – a study conducted in large groups of patients of various ages and with various concomitant conditions in order to examine all aspects of treatment, including assessment of the risk: benefit ratio.

No. Abbreviations

- a. **IB** – Investigator's Brochure
- b. **PI** – Principal Investigator
- c. **RT** – research team
- d. **MD** – medical device
- e. **IP** – investigational product
- f. **CRF** – case report form
- g. **IC** – informed consent
- h. **CT** – clinical trial
- i. **CTC** – clinical trial coordinator
- j. **LEC** – Local Bioethics Committee of HemCenter LLP
- k. **MoH RK** – Ministry of Health of the Republic of Kazakhstan
- l. **AE** – adverse event
- m. **ED** – essential documents
- n. **RK** – Republic of Kazakhstan
- o. **SAR** – serious adverse reaction
- p. **SAE** – serious adverse event
- q. **SOP** – standard operating procedure
- r. **LLP** – limited liability partnership
- s. **the Center** – HemCenter LLP
- t. **CBC** – Central Bioethics Commission of the Ministry of Health of the Republic of Kazakhstan
- u. **ҚР ДСМ** – abbreviation used when assigning numbers to regulatory legal acts of the RK (Kazakh)
- v. **CRO** – contract research organization
- w. **GCP** – Good Clinical Practice
- x. **ICH-GCP** – International Conference on Harmonisation, the international conference on the harmonisation of GCP
- y. **CIOMS** – Council for International Organizations of Medical Sciences

Type	SOP	Nomenclature code	I-05	Number	Issl-3-19	Revision	001
Title	EXTRAORDINARY LEC MEETINGS						

- z. **EMEA** – European Medicines Agency (EMA), the agency for the evaluation of medicinal products for compliance with the requirements set out in the European Pharmacopoeia
- aa. **FDA** – Food and Drug Administration of the USA (United States of America)
- bb. **UNESCO** – United Nations Educational, Scientific and Cultural Organization, a specialised agency of the United Nations for education, science and culture.
- cc. **WHO** – World Health Organization

No. Procedure

1. Emergency meetings of the LEC may be scheduled for the review of/decision-making on matters of safety where there is a threat to the life of study participants, new studies, additional investigators, continuing review, protocol amendments and other activities requiring the presence of all LEC members.
When reviewing ordinary medical studies, a healthcare professional may be invited to take part in the emergency meeting of the LEC in order to provide detailed information on the medical care given to study participants.
2. Before the LEC meeting, the Chair decides to convene an emergency meeting on the basis of the following criteria: matters requiring immediate consideration that may affect the benefit to society, the national economy, etc.; the occurrence of unexpected and serious adverse events; matters of life and death; and other reasons
The LEC Chair informs the LEC members and invited persons of the meeting, including at least one scientific member, one non-scientific member of the committee, an expert on the matter under consideration and a healthcare professional. One expert must also be invited to examine the documents.
The LEC Secretary prepares the document package for the participants of the emergency meeting.
The LEC Secretary draws up the attendance sheet of the meeting participants, indicating the date, time, list of participants, their telephone numbers, the number of the meeting minutes and the participants' signatures as confirmation of their attendance.
3. During the meeting, the quorum must be established and the following SOPs must be followed: "Process for Submitting an Application for Review of the Study Document Package (study protocol, etc.)"; "Study Assessment", "Expedited Review of the Study Document Package" and "Initial Consideration of Study Documentation (applications, study protocols)"

Governing documents

1. Code of the Republic of Kazakhstan "On Public Health and the Healthcare System" No. 360-VI ZRK dated 7 July 2020. [Link](#)
2. Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 248/2020 dated 11 December 2020 "On approval of the rules for conducting clinical trials of medicinal products and medical devices, clinical laboratory testing of medical devices for diagnostics outside a living organism (in vitro), and the requirements for clinical sites, and for the provision of the public service Issuance of authorisation to conduct a clinical trial and (or) testing of pharmacological and medicinal products and medical devices". [Link](#)
3. Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 35 dated 4 April 2022, registered with the Ministry of Justice of the Republic of Kazakhstan on 12 April 2022 under No. 27526, on amendments and additions to Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 248/2020 dated 11 December 2020 "On approval of the rules for conducting clinical trials of medicinal products and medical devices, clinical laboratory testing of medical devices for diagnostics outside a living organism (in vitro), and the requirements for clinical sites, and for the provision of the public service Issuance of authorisation to conduct a clinical trial and (or) testing of pharmacological and medicinal products and medical devices". [Link](#)
4. Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 310/2020 dated 21 December 2020 "On approval of the rules for conducting biomedical research and the requirements for research centres". [Link](#)

Type	SOP	Nomenclature code	I-05	Number	Issl-3-19	Revision	001
Title	EXTRAORDINARY LEC MEETINGS						

5. Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 181/2020 dated 4 November 2020 "On approval of the rules for assessing, within the framework of pharmaceutical inspection, the materials of preclinical (non-clinical) studies and the compliance of the conditions for conducting them with the requirements of Good Laboratory Practice (GLP) of the Republic of Kazakhstan and (or) the Eurasian Economic Union". [Link](#)
6. Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 151/2020 dated 23 October 2020 "On approval of the Regulation on the Central Bioethics Commission". [Link](#)
7. Order of the Acting Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 130 dated 20 December 2021 "On approval of the standard for the organisation of haematological care for the adult population of the Republic of Kazakhstan". [Link](#)
8. Order of the Acting Minister of Health of the Republic of Kazakhstan dated 4 February 2021 No. ҚР ДСМ-
15. Registered with the Ministry of Justice of the Republic of Kazakhstan on 9 February 2021 under No. 2216, "On approval of good pharmaceutical practices". [Link](#)
9. Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 304/2020 dated 21 December 2020. Registered with the Ministry of Justice of the Republic of Kazakhstan on 22 December 2020 under No. 21848, "On approval of the regulations on the clinical site, the clinic of a healthcare education organisation, the university hospital, the residency site and the integrated academic medical centre, and the requirements for them". [Link](#)
10. Order of the Minister of Health of the Republic of Kazakhstan No. ҚР ДСМ- 299/2020 dated 21 December 2020 "On approval of the rules for accreditation in the field of healthcare". [Link](#)
11. Standard ISO14155:2014№ "Clinical investigations. Good Clinical Practice". [Link](#)
12. Recommendation of the Board of the Eurasian Economic Commission No. 11 dated 17 July 2018 "On the Guideline on general issues of clinical trials". [Link](#)
13. Decision of the Council of the Eurasian Economic Commission No. 79 dated 3 November 2016 "On approval of the Rules of Good Clinical Practice of the Eurasian Economic Union". [Link](#)
14. Recommendation of the Board of the Eurasian Economic Commission No. 19 dated 3 November 2020 "On the Guideline on the application of biostatistics principles in clinical trials of medicinal products". [Link](#)
15. Recommendation of the Board of the Eurasian Economic Commission No. 18 dated 27 October 2020 "On the Guideline on safety pharmacology studies of medicinal products for human use".
16. Decision of the Council of the Eurasian Economic Commission No. 85 dated 3 November 2016 "On approval of the Rules for conducting bioequivalence studies of medicinal products within the Eurasian Economic Union". [Link](#)
17. Declaration of Helsinki of the World Medical Association, June 1964 (latest revision of 9 July 2018). [Link](#)
18. Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants, World Health Organization (2011); and other international declarations and guidelines in the field of research ethics (WHO, ICH-GCP, UNESCO, CIOMS, CE).
19. Regulation on the Local Bioethics Committee (hereinafter- the LEC or the Committee) of HemCenter LLP, approved by Order No. I-02-44 dated 31 June 2023
20. Rules for conducting clinical trials and scientific research at HemCenter LLP, approved by Order No. I-02-47 dated 31 June 2023
21. Job descriptions of the Local Bioethics Committee of HemCenter LLP dated 31 June 2023.
22. Other regulatory legal acts of the Republic of Kazakhstan governing clinical trials.

Related documents

No.	type	title
Issl-3-4	SOP	Process of Submitting an Application for Review of the Study Document Package (Study Protocol, etc.)

Type	SOP	Nomenclature code	I-05	Number	Issl-3-19	Revision	001
Title	EXTRAORDINARY LEC MEETINGS						
Issl-3-5	SOP		Assessment of a Study Application				
Issl-3-7	SOP		Expedited Review of the Study Document Package				
Issl-3-6	SOP		Initial Consideration of Study Documentation (applications, study protocols)				
Issl-3-2	SOP		Maintaining confidentiality in the work of the LEC				

List of changes

Rev. No. Date	Order No. List of changes Change of the SOP form, corrections to terminology based on amendments/additions to the regulatory legal acts of the RK, corrections throughout the text
---------------	---

Document acknowledgement list

No.	Full name	Position	Date	Signature
1.				
2.				
3.				
4.				
5.				
6.				
7.				
8.				
9.				
10.				
11.				
12.				
13.				
14.				
15.				
16.				
17.				
18.				
19.				
20.				
21.				
22.				
23.				
24.				
25.				
26.				
27.				
28.				
29.				
30.				